RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
0.8122
-0.0177 (-2.13%)
At close: Jul 2, 2026, 4:00 PM EDT
0.8364
+0.0242 (2.98%)
After-hours: Jul 2, 2026, 7:26 PM EDT
RedHill Biopharma Revenue
In the year 2025, RedHill Biopharma had annual revenue of $286.00K. RedHill Biopharma had revenue of $-3.79M in the half year ending December 31, 2025.
Revenue (ttm)
$286.00K
Revenue Growth
-95.13%
P/S Ratio
17.27
Revenue / Employee
$22,000
Employees
13
Market Cap
4.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 286.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 61.80M | -23.96M | -27.94% |
| Dec 31, 2021 | 85.76M | 21.40M | 33.25% |
| Dec 31, 2020 | 64.36M | 58.07M | 923.03% |
| Dec 31, 2019 | 6.29M | -2.07M | -24.75% |
| Dec 31, 2018 | 8.36M | 4.35M | 108.63% |
| Dec 31, 2017 | 4.01M | 3.91M | 3,867.33% |
| Dec 31, 2016 | 101.00K | 98.00K | 3,266.67% |
| Dec 31, 2015 | 3.00K | -7.01M | -99.96% |
| Dec 31, 2014 | 7.01M | 7.00M | 58,350.00% |
| Dec 31, 2013 | 12.00K | -4.00K | -25.00% |
| Dec 31, 2012 | 16.00K | -7.00K | -30.43% |
| Dec 31, 2011 | 23.00K | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 43.20M |
| Sunshine Biopharma | 35.49M |
| cbdMD | 19.98M |
| Sonoma Pharmaceuticals | 19.53M |
| Universe Pharmaceuticals INC | 17.86M |
| InMed Pharmaceuticals | 4.94M |
| Akanda | 258.08K |
| Gelteq | 186.08K |
RDHL News
- 1 day ago - RedHill Biopharma Registration statement: Registration filing - Filings
- 2 days ago - RedHill Biopharma Slides: Corporate presentation - Filings
- 10 days ago - RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement - PRNewsWire
- 15 days ago - RedHill Biopharma announces $19.4M private placement - TheFly
- 15 days ago - RedHill Biopharma Announces Up To $19.4 Million Private Placement - PRNewsWire
- 17 days ago - RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside - TipRanks
- 22 days ago - RedHill Biopharma’s Opaganib Ebola Plan Gives RDHL Stock a New Catalyst - TipRanks
- 24 days ago - RedHill Biopharma’s opaganib granted FDA Rare Pediatric Disease designation - TheFly